ArticleScientific reports2024

Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma.

Keitaro Iida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.